Antivirales (a excepción del virus de la inmunodeficiencia humana y la hepatitis)

Sobieszczyk, 2009, Antiretroviral agents, 167 Yin, 2009, Antiherpesvirus? anti-hepatitis virus and anti-respiratory virus agents, 217 Coen, 2013, Antiviral Agents, 338 Frobert, 2019, Chimiothérapie antivirale, 153 Chambon, 1999, Antiseptiques, désinfectants chimiques et virus en secteur médical, Virologie, 3, 367 Barin, 2019, Multiplication des virus dans l’organisme et relations hôte-virus, 45 Vitiello, 2021, Low molecular weight heparin, anti-inflammatory/immunoregulatory and antiviral effects, a short update, Cardiovasc Drugs Ther, 30, 1 Hans, 2021, Antiviral activity of sulfated polysaccharides from marine algae and its application in combating COVID-19: mini review, Bioresour Technol Rep, 13, 100623, 10.1016/j.biteb.2020.100623 De Clercq, 2015, Development of antiviral drugs for the treatment of hepatitis C at an accelerating pace, Rev Med Virol, 25, 254, 10.1002/rmv.1842 Tian, 2021, RNA-dependent polymerase (RdRp) inhibitors: the current landscape and repurposing for the COVID-19 pandemic, Eur J Med Chem, 213, 113201, 10.1016/j.ejmech.2021.113201 Morfin, 2007, Nouvelles cibles pour le développement de molécules antiherpétiques, Virologie, 11, 423 Jeulin, 2009, Quel avenir pour la ribavirine en dehors de l’hépatite C ?, Virologie, 13, 83 De Clercq, 2016, Approved antiviral drugs over the past 50 years, Clin Microbiol Rev, 29, 695, 10.1128/CMR.00102-15 Razonable, 2013, Clinical utility of viral load in management of cytomegalovirus infection after solid organ transplantation, Clin Microbiol Rev, 26, 703, 10.1128/CMR.00015-13 Jakharia, 2021, CMV infection in hematopoietic stem cell transplantation: prevention and treatment strategies, Curr Treat Options Infect Dis, 1 Agut, 2009, Testing the susceptibility of human herpesviruses to antivirals, Future Microbiol, 4, 1111, 10.2217/fmb.09.83 Chemaly, 2019, In vitro comparison of currently available and investigational antiviral agents against pathogenic human double-stranded DNA viruses: a systematic literature review, Antiviral Res, 163, 50, 10.1016/j.antiviral.2019.01.008 Tompa, 2021, Trends and strategies to combat viral infections: a review on FDA approved antiviral drugs, Int J Biol Macromol, 172, 524, 10.1016/j.ijbiomac.2021.01.076 Burrel, 2013, Surveillance of herpes simplex virus resistance to antivirals: a 4-year survey, Antiviral Res, 100, 365, 10.1016/j.antiviral.2013.09.012 Agut, 2015, Laboratory and clinical aspects of human herpesvirus 6 infections, Clin Microbiol Rev, 28, 313, 10.1128/CMR.00122-14 De Clercq, 2013, Selective anti-herpesvirus agents, Antivir Chem Chemother, 23, 93, 10.3851/IMP2533 De Clercq, 2011, The clinical potential of the acyclic (and cyclic) nucleoside phosphonates: the magic of the phosphonate bond, Biochem Pharmacol, 82, 99, 10.1016/j.bcp.2011.03.027 Deback, 2015, Management of multidrug-resistant CMV infection in immunocompromised patients: case report of a heart-transplant recipient and review of the literature, Antivir Ther, 20, 249, 10.3851/IMP2818 Whitley, 2014, A novel potential therapy for HSV, N Engl J Med, 370, 273, 10.1056/NEJMe1313982 Shiraki, 2021, Amenamevir, a helicase-primase inhibitor, for the optimal treatment of herpes zoster, Viruses, 13, 1547, 10.3390/v13081547 Melendez, 2015, Letermovir and inhibitors of the terminase complex: a promising new class of investigational antiviral drugs against human cytomegalovirus, Infect Drug Resist, 8, 269 Chou, 2011, The unique antiviral activity of artesunate is broadly effective against human cytomegaloviruses including therapy-resistant mutants, Antiviral Res, 92, 364, 10.1016/j.antiviral.2011.07.018 Roy, 2015, Inhibition of human cytomegalovirus replication by artemisinins: effects mediated through cell cycle modulation, Antimicrob Agents Chemother, 59, 3870, 10.1128/AAC.00262-15 Duraffour, 2015, ST-246 is a key antiviral to inhibit the viral F13L phospholipase, one of the essential proteins for orthopoxvirus wrapping, J Antimicrob Chemother, 70, 1367, 10.1093/jac/dku545 Delaune, 2020, Drug development against smallpox: present and future, Antimicrob Agents Chemother, 64, e01683, 10.1128/AAC.01683-19 Tao, 2021, SARS-CoV-2 antiviral therapy, Clin Microbiol Rev, 34, e00109, 10.1128/CMR.00109-21 Nyström, 2019, Ribavirin: pharmacology, multiple modes of action and possible future perspectives, Future Virol, 14, 153, 10.2217/fvl-2018-0166 Salmona, 2021, Quelles molécules pour traiter des infections à adénovirus ?, Virologie, 25, 43 Beigel, 2020, Remdesivir for the treatment of covid-19 - final report, N Engl J Med, 383, 1813, 10.1056/NEJMoa2007764 Shirley, 2020, Baloxavir marboxil: a review in acute uncomplicated influenza, Drugs, 80, 1109, 10.1007/s40265-020-01350-8 Kuo, 2021, Clinical efficacy and safety of baloxavir marboxil in the treatment of influenza: a systematic review and meta-analysis of randomized controlled trials, J Microbiol Immunol Infect, 10.1016/j.jmii.2021.04.002 Taylor, 2021, Neutralizing monoclonal antibodies for treatment of COVID-19, Nat Rev Immunol, 21, 382, 10.1038/s41577-021-00542-x Adamson, 2021, Antiviral drug discovery: preparing for the next pandemic, Chem Soc Rev, 50, 3647, 10.1039/D0CS01118E Fuzimoto, 2021, An overview of the anti-SARS-CoV-2 properties of Artemisia annua, its antiviral action, protein-associated mechanisms, and repurposing for COVID-19 treatment, J Integr Med, 10.1016/j.joim.2021.07.003 Mslati, 2021, Comprehensive consensus analysis of SARS-CoV-2 drug repurposing campaigns, J Chem Inf Model, 61, 3771, 10.1021/acs.jcim.1c00384 Gatti, 2021, Janus kinase inhibitors and coronavirus disease (COVID)-19: rationale, clinical evidence and safety issues, Pharmaceuticals, 738, 10.3390/ph14080738 Ghosh, 2012, Histone deacetylase inhibitors are potent inducers of gene expression in latent EBV and sensitize lymphoma cells to nucleoside antiviral agents, Blood, 119, 1008, 10.1182/blood-2011-06-362434